Certara Launches Next Generation CoAuthor™ Generative AI Regulatory Writing Software
AI-enabled solutions accelerate regulatory and medical writing processes, enhancing quality, transparency, and efficiencies RADNOR, PA…
CertaraJune 17, 2024
Introducing CoAuthor™: The Gen-AI Enabled Solution for Regulatory Writers
Faced with more (and more complex) clinical research than ever before, regulatory writers are facing…
CertaraJune 14, 2024
Certara Recognized as a Top Biopharma Workplace for 2024
RADNOR, PA – June 12, 2024 – Certara, Inc. (Nasdaq: CERT), a global leader in…
CertaraJune 12, 2024
How QSP Brings Insights and Accelerates Bispecific Antibody Drug Development [China Webinar]
More than 50 bispecific antibodies are in oncology clinical development with a large diversity in…
CertaraJune 7, 2024
Adaptive Trial Design for Phase 1 Dose-Finding Studies
Greater flexibility, efficiency and quicker dissemination of research findings to patient communities that stand to…
CertaraJune 7, 2024
A Best Practice Guide to CRF Design
Design quality, effective and reusable case report forms with our CRF Design Guide. Download the…
CertaraJune 7, 2024
The State of Generative AI in Life Sciences
Discover how Generative AI in life sciences can transform drug discovery, clinical trials, and lab…
CertaraJune 7, 2024
Technology Networks: Deregulating Psychedelics To Propel Clinical Research
Deregulating certain psychedelics could help to address unmet patient needs.
CertaraJune 6, 2024
